Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is the evaluation of effect of circadian gene on sleep and other symptoms in breast cancer patients under chemotherapy.
In this study, the investigators are going to examine the effect of genetic polymorphism on sleep, anxiety, depression and other cancer-related symptoms in patients with breast cancer who have started chemotherapy after surgery. No intervention was intended and blood sample was taken with other routine laboratory tests.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| breast cancer | breast cancer patients receiving chemotherapy |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Changes from Baseline Sleep Impairment at 1 Month After Chemotherapy | Sleep impairment will be evaluated by questionnaires before chemotherapy. The evaluation will be followed 1 month, 3 months after starting chemotherapy. The final evaluation will be done 1 month after completion of the chemotherapy. | baseline, 1 month, 3 months, 1 month after chemotherpy completion |
| Measure | Description | Time Frame |
|---|---|---|
| Changes from Baseline Quality of Life at 1 Month After Chemotherapy | Quality of life will be evaluated by questionnaires before chemotherapy. The evaluation will be followed 1 month after completion of the chemotherapy. | baseline, 1 month after chemotherpy completion |
| Changes from Baseline Cancer-related Symptoms at 1 Month After Chemotherapy |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
university hospital, oncology clinic
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bong-Jin Hahm, MD, PhD | Seoul National University Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Seoul National University Hospital | Seoul | Jongno-gu | 140-013 | South Korea |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 35132840 | Derived | Son KL, Jung D, Lee KM, Yeom CW, Oh GH, Kim TY, Im SA, Lee KH, Spiegel D, Hahm BJ. Morning Chronotype Decreases the Risk of Chemotherapy-Induced Peripheral Neuropathy in Women With Breast Cancer. J Korean Med Sci. 2022 Feb 7;37(5):e34. doi: 10.3346/jkms.2022.37.e34. |
| Label | URL |
|---|---|
| study site | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| D001943 | Breast Neoplasms |
| D001008 | Anxiety Disorders |
| D003863 | Depression |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
whole blood, serum
Cancer-related symptoms will be evaluated by questionnaires before chemotherapy. The evaluation will be followed 1 month, 3 months after starting chemotherapy. The final evaluation will be done 1 month after completion of the chemotherapy. |
| baseline, 1 month, 3 months, 1 month after chemotherpy completion |
| Changes from Baseline Fatigue at 1 Month After Chemotherapy | Fatigue will be evaluated by questionnaires before chemotherapy. The evaluation will be followed 1 month, 3 months after starting chemotherapy. The final evaluation will be done 1 month after completion of the chemotherapy. | baseline, 1 month, 3 months, 1 month after chemotherpy completion |
| Changes from Baseline Depression at 1 Month After Chemotherapy | Depression will be evaluated by questionnaires before chemotherapy. The evaluation will be followed 1 month, 3 months after starting chemotherapy. The final evaluation will be done 1 month after completion of the chemotherapy. | baseline, 1 month, 3 months, 1 month after chemotherpy completion |
| Changes from Baseline Anxiety 1 Month After Chemotherapy | Anxiety will be evaluated by questionnaires before chemotherapy. The evaluation will be followed 1 month, 3 months after starting chemotherapy. The final evaluation will be done 1 month after completion of the chemotherapy. | baseline, 1 month, 3 months, 1 month after chemotherpy completion |
| Changes from Baseline PTSD Symptoms 1 Month After Chemotherapy | PTSD symptoms will be evaluated by questionnaires before chemotherapy. The evaluation will be followed 1 month, 3 months after starting chemotherapy. The final evaluation will be done 1 month after completion of the chemotherapy. | baseline, 1 month, 3 months, 1 month after chemotherpy completion |
| Changes from Baseline Menopausal Symptoms 1 Month After Chemotherapy | Menopausal symptoms will be evaluated by questionnaires before chemotherapy. The evaluation will be followed 1 month, 3 months after starting chemotherapy. The final evaluation will be done 1 month after completion of the chemotherapy. | baseline, 1 month, 3 months, 1 month after chemotherpy completion |
| D017437 |
| Skin and Connective Tissue Diseases |
| D001523 | Mental Disorders |
| D001526 | Behavioral Symptoms |
| D001519 | Behavior |